#auph

This text was written by Observe Gamu Dave Harmless Pasi is a seasoned monetary skilled and author, bringing a wealth of expertise from his prior roles as a monetary analyst and in funding analysis. With a powerful background in analyzing monetary statements, capital markets, and the macro-economy, Gamu has a confirmed observe report of offering actionable buying and selling concepts and…

Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot

— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.

— Revenue remained flat at $29,000 versus $40,000 expected. The top line was hurt by nil contract revenue.

— The bottom line was hurt by an increase in the estimated fair value of derivative warrant liabilities.

— Research and development expenses…

Aurinia Pharmaceuticals (NASDAQ: AUPH): Q3 2019 Earnings Snapshot

— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.

— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.

— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes…

Motley Fool: Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

Image source: The Motley Fool.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Q4 2018 Earnings Conference Call March 19, 2019, 4:30 p.m. ET

Contents:

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Greetings and welcome to the Aurinia fourth quarter and full year 2018 financial results and operational highlights conference call. At this time, all participants are…

Aurinia to report Q4 earnings results after the bell

Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) is set to report its fourth quarter and full-year 2018 results today after the market closes. Street expects Q4 loss to narrow by 8 cents to $0.14 over the prior year, while sales is expected to jump 33% over last year. Shares of Aurinia rose about 2% in today’s afternoon trading.

(Check out this space for more updates)

Aurinia stock climbed 13% on…

Earnings Preview: Aurinia’s Q4 results pivot on AURORA trial updates

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) rose 13% on February 25 when the US patent office extended the patent protection for voclosporin till 2037 in treating patients diagnosed with lupus nephritis. Investors cheered up the news as this would give the firm market exclusivity for nearly two decades once the drug gets approved and hits the market.

With the positive momentum, the…

AUPH Aurinia Pharmaceuticals bullish supportline Right now, Aurinia Pharmaceuticals is testing supportline. Also Moving Averages 100 is being tested right now. Now is a good place to take a position and wait for profit. The first profit takingcan be at price 6.00 and 2. target will be around 7.00. Stoploss can be around 5.3. We will put this stock on our watchlist and wait for a green candle above the supportline. AUPH Aurinia Pharmaceuticals bullish supportline